ENA-001 Reverses Xylazine/Fentanyl Combination-Induced Respiratory Depression in Rats: A Qualitative Pilot Study

Area of Science:

• Pharmacology
• Toxicology
• Respiratory Medicine

Background:

• Xylazine exacerbates fentanyl-induced respiratory depression.
• Xylazine, a non-opioid, is resistant to naloxone reversal, complicating overdose treatment.
• Large-conductance potassium channel (BK_Ca) antagonists can reverse drug-induced respiratory issues.

Purpose of the Study:

• To evaluate ENA-001's potential to mitigate respiratory depression caused by xylazine-fentanyl combination (XFC) overdose.
• To assess ENA-001 as an agnostic respiratory reversal agent for XFC overdose.

Main Methods:

• A pilot study in rats was conducted.
• Rats received an intravenous bolus of xylazine-fentanyl combination (XFC).
• The effect of a single intravenous bolus of ENA-001 or vehicle on XFC-induced respiratory depression was measured.

Main Results:

• XFC-induced respiratory depression was characterized by decreased pO2 and increased pCO2.
• ENA-001 administration rapidly reversed these XFC-induced changes.
• Vehicle administration did not reverse the XFC-induced respiratory depression.

Conclusions:

• ENA-001 demonstrated efficacy in reversing respiratory depression from XFC overdose in rats.
• The agnostic respiratory stimulating properties of ENA-001 appear to extend to XFC overdose.
• Further investigation of ENA-001 is warranted due to the urgent clinical need for effective overdose treatments.